Henry Schein (NASDAQ:HSIC) Price Target Raised to $87.00

Henry Schein (NASDAQ:HSIC) had its price objective lifted by UBS Group from $79.00 to $87.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other equities research analysts have also weighed in on HSIC. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Mizuho boosted their price objective on shares of Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research report on Wednesday. Evercore raised their target price on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Finally, Robert W. Baird set a $100.00 target price on shares of Henry Schein and gave the company an “outperform” rating in a research note on Monday. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Henry Schein presently has an average rating of “Hold” and an average price target of $85.58.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $82.39 on Wednesday. The firm has a market cap of $9.45 billion, a PE ratio of 25.20, a price-to-earnings-growth ratio of 2.41 and a beta of 0.88. The company’s fifty day simple moving average is $77.85 and its two-hundred day simple moving average is $72.15. The company has a quick ratio of 0.79, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. Henry Schein has a 12-month low of $60.56 and a 12-month high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same period in the prior year, the business posted $1.19 earnings per share. Henry Schein’s revenue for the quarter was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities analysts expect that Henry Schein will post 4.74 EPS for the current year.

Insider Buying and Selling

In related news, CEO Stanley M. Bergman sold 10,785 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $81.20, for a total value of $875,742.00. Following the transaction, the chief executive officer owned 309,092 shares in the company, valued at $25,098,270.40. The trade was a 3.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.08% of the company’s stock.

Institutional Investors Weigh In On Henry Schein

Institutional investors have recently modified their holdings of the business. MAI Capital Management grew its stake in shares of Henry Schein by 7.5% in the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock worth $137,000 after acquiring an additional 144 shares during the period. CW Advisors LLC boosted its holdings in Henry Schein by 2.8% in the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock worth $432,000 after purchasing an additional 163 shares during the last quarter. Truist Financial Corp boosted its holdings in Henry Schein by 3.3% in the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after purchasing an additional 175 shares during the last quarter. Simon Quick Advisors LLC grew its position in Henry Schein by 5.5% in the 2nd quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after purchasing an additional 182 shares during the period. Finally, Claret Asset Management Corp raised its stake in Henry Schein by 6.3% during the 2nd quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock valued at $232,000 after buying an additional 187 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.